74 studies on Glucagon agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
Establishing bioequivalence between different drug formulations is crucial for drug development. It ensures that any changes in formulation (e.g., for improved stability, manufacturing, or patient convenience) do not …
Optimizing Survodutide's formulation is critical for its future development as a potential treatment for obesity and NASH. A formulation with improved bioavailability could lead to more effective dosing strategies, po…
The successful completion of this Phase 1/2 study marks a critical developmental milestone for IBI362 as a potential therapeutic agent for overweight and obesity. Establishing the initial safety profile and understand…
The successful outcome of this Phase III trial could represent a significant advancement in the treatment of overweight and obesity, particularly for the Chinese population, where specific therapeutic options are high…
This large-scale registry is crucial for understanding the current state of obesity and Type 2 Diabetes Mellitus management in China, a region with unique dietary and lifestyle factors. The real-world data collected w…
The successful completion of enrollment for this Phase III trial is a significant milestone in the development of new therapies for NASH and obesity. Given the limited treatment options for NASH, a condition affecting…
This Phase 1 study is crucial for the continued development of survodutide, as it provides foundational data on how the drug behaves in a specific ethnic population. Understanding the pharmacokinetics and safety profi…
The first approval of Mazdutide in China is a pivotal development, introducing a novel dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist to the therapeutic landscape. This provides a …
PCOS is a complex condition with significant unmet medical needs, particularly for obese patients struggling with hyperandrogenism and metabolic dysfunction. If Mazdutide proves effective in reducing FAI, it could rep…
Understanding how renal impairment affects IBI362's pharmacokinetics is critically important for patient safety and treatment efficacy. If kidney function significantly alters drug exposure, dose adjustments will be n…
Optimizing drug formulation is crucial for enhancing patient convenience, adherence, and ultimately, therapeutic efficacy for conditions like obesity and MASH. If Formulation B2 demonstrates superior or comparable bio…
Understanding the specific receptor binding profiles of BI 456906 is a critical first step in evaluating its potential as a novel therapeutic agent for obesity. If BI 456906 demonstrates significant and distinct gluca…
This Phase 1 study is critically important as it seeks to understand the fundamental metabolic mechanisms of survodutide, a novel therapeutic candidate for obesity. If survodutide demonstrates superior or distinct ben…
Establishing bioequivalence between different delivery devices for Survodutide is a critical step for its future clinical development and patient accessibility. If the pre-filled syringe and pen deliver the drug equiv…
If successful, this Phase 2 trial could represent a significant advancement in the treatment of chronic kidney disease, a condition with high morbidity and mortality. A drug that can effectively reduce albuminuria cou…
This large-scale Phase 3 trial is crucial for understanding the long-term cardiovascular impact of survodutide, a novel anti-obesity agent. A positive outcome would establish survodutide as a safe and effective treatm…
The successful outcome of this Phase III trial could represent a monumental step forward in treating MASH, a condition affecting millions globally with no current pharmacological cure. If Survodutide demonstrates sign…
The bold challenge of weight regain after successful initial weight loss significantly impacts long-term health outcomes for individuals with obesity. If Retatrutide proves effective in maintaining weight reduction, i…
This trial is crucial because retatrutide, a novel triple agonist targeting GIP, GLP-1, and glucagon receptors, holds significant promise for treating obesity and its complex comorbidities. If successful, it could off…
If successful, this trial could represent a significant advancement for patients with Type 2 Diabetes and renal impairment, a group with limited treatment options and high unmet medical need. Retatrutide could offer a…
The successful modulation of calorie intake and energy expenditure by LY3437943 could represent a significant advancement in obesity treatment. If LY3437943 demonstrates a favorable impact on these parameters, it coul…
If successful, this study could demonstrate a significant cardio-renal protective effect of Retatrutide beyond its known weight-loss benefits. This would be a crucial advancement, as current treatments for obesity oft…
The SYNERGY-OUTCOMES study holds immense significance as it addresses a critical unmet medical need for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition without approved pharmacologic trea…
If successful, this Phase 2 study could demonstrate that LY3437943 is a highly effective and well-tolerated treatment for obesity and overweight with comorbidities, potentially offering a new therapeutic avenue. The e…
A favorable drug-drug interaction profile is a critical factor for the successful development of any new medication, particularly for chronic conditions like obesity where patients often take multiple concomitant drug…
This Phase 3b trial is pivotal for optimizing Retatrutide's clinical utility by identifying the most effective and well-tolerated dosing strategies for long-term use. Understanding the nuances of dose escalation can s…
If Retatrutide demonstrates a positive impact on renal function, it could represent a significant advancement in treating complex metabolic and renal diseases. As a triple GIP/GLP-1/glucagon receptor agonist, Retatrut…
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, showing promise in weight loss and glucose control in earlier studies. If this Phase 1 trial demonstrates a significant positive impa…